

Daniel Weintraub

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7484166/publications.pdf>

Version: 2024-02-01

358
papers

36,876
citations

3325

91
h-index

3815

178
g-index

377
all docs

377
docs citations

377
times ranked

21675
citing authors

#	ARTICLE	IF	CITATIONS
1	Diagnosis and management of dementia with Lewy bodies. <i>Neurology</i> , 2017, 89, 88-100.	1.5	2,805
2	Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. <i>Movement Disorders</i> , 2012, 27, 349-356.	2.2	1,908
3	Impulse Control Disorders in Parkinson Disease. <i>Archives of Neurology</i> , 2010, 67, 589-95.	4.9	1,244
4	Effectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimer's Disease. <i>New England Journal of Medicine</i> , 2006, 355, 1525-1538.	13.9	1,067
5	Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease. <i>Neurology</i> , 2009, 73, 1738-1745.	1.5	946
6	The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, S42-80.	2.2	863
7	Cognitive decline in Parkinson disease. <i>Nature Reviews Neurology</i> , 2017, 13, 217-231.	4.9	705
8	MDS task force on mild cognitive impairment in Parkinson's disease: Critical review of PD-MCI. <i>Movement Disorders</i> , 2011, 26, 1814-1824.	2.2	649
9	Mild cognitive impairment in Parkinson disease. <i>Neurology</i> , 2010, 75, 1062-1069.	1.5	643
10	Update on treatments for nonmotor symptoms of Parkinson's disease—an evidence-based medicine review. <i>Movement Disorders</i> , 2019, 34, 180-198.	2.2	619
11	Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy. <i>Movement Disorders</i> , 2017, 32, 1264-1310.	2.2	608
12	Association of Dopamine Agonist Use With Impulse Control Disorders in Parkinson Disease. <i>Archives of Neurology</i> , 2006, 63, 969.	4.9	601
13	Depression rating scales in Parkinson's disease: Critique and recommendations. <i>Movement Disorders</i> , 2007, 22, 1077-1092.	2.2	583
14	Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2010, 9, 573-580.	4.9	476
15	Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated. <i>Brain</i> , 2018, 141, 2181-2193.	3.7	448
16	Effect of Citalopram on Agitation in Alzheimer Disease. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 682.	3.8	447
17	Validation of the questionnaire for impulsive-compulsive disorders in Parkinson's disease. <i>Movement Disorders</i> , 2009, 24, 1461-1467.	2.2	394
18	Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis. <i>Lancet Neurology</i> , The, 2017, 16, 55-65.	4.9	394

#	ARTICLE	IF	CITATIONS
19	Parkinson disease-associated cognitive impairment. <i>Nature Reviews Disease Primers</i> , 2021, 7, 47.	18.1	391
20	Impulse control disorders in parkinson disease: A multicenter caseâ€“control study. <i>Annals of Neurology</i> , 2011, 69, 986-996.	2.8	361
21	Parkinson's disease: The quintessential neuropsychiatric disorder. <i>Movement Disorders</i> , 2011, 26, 1022-1031.	2.2	349
22	Effect of Psychiatric and Other Nonmotor Symptoms on Disability in Parkinson's Disease. <i>Journal of the American Geriatrics Society</i> , 2004, 52, 784-788.	1.3	333
23	The Parkinson's progression markers initiative (PPMI) â€“ establishing a PD biomarker cohort. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 1460-1477.	1.7	330
24	CSF amyloid β 1-42 predicts cognitive decline in Parkinson disease. <i>Neurology</i> , 2010, 75, 1055-1061.	1.5	315
25	Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson's disease: a cohort study. <i>Lancet Neurology</i> , The, 2017, 16, 66-75.	4.9	304
26	APOE ϵ 4 Increases Risk for Dementia in Pure Synucleinopathies. <i>JAMA Neurology</i> , 2013, 70, 223.	4.5	302
27	Apathy and anhedonia rating scales in Parkinson's disease: Critique and recommendations. <i>Movement Disorders</i> , 2008, 23, 2004-2014.	2.2	285
28	The impact of depressive symptoms in early Parkinson disease. <i>Neurology</i> , 2007, 69, 342-347.	1.5	278
29	Montreal Cognitive Assessment Performance in Patients with Parkinson's Disease with â€œNormalâ€“ Global Cognition According to Miniâ€“Mental State Examination Score. <i>Journal of the American Geriatrics Society</i> , 2009, 57, 304-308.	1.3	270
30	Clinical spectrum of impulse control disorders in Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 121-127.	2.2	264
31	Questionnaire for impulsiveâ€“compulsive disorders in Parkinson's Diseaseâ€“Rating Scale. <i>Movement Disorders</i> , 2012, 27, 242-247.	2.2	263
32	The psychosis spectrum in Parkinson disease. <i>Nature Reviews Neurology</i> , 2017, 13, 81-95.	4.9	252
33	Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 919-927.	2.2	244
34	Comparison and predictors of rash associated with 15 antiepileptic drugs. <i>Neurology</i> , 2007, 68, 1701-1709.	1.5	228
35	Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease. <i>Neurology</i> , 2010, 75, 448-455.	1.5	219
36	Longâ€“term followâ€“up of impulse control disorders in Parkinson's disease. <i>Movement Disorders</i> , 2008, 23, 75-80.	2.2	213

#	ARTICLE	IF	CITATIONS
37	Anxiety rating scales in Parkinson's disease: Critique and recommendations. <i>Movement Disorders</i> , 2008, 23, 2015-2025.	2.2	208
38	Test Characteristics of the 15-Item Geriatric Depression Scale and Hamilton Depression Rating Scale in Parkinson Disease. <i>American Journal of Geriatric Psychiatry</i> , 2006, 14, 169-175.	0.6	205
39	Sertraline for the Treatment of Depression in Alzheimer Disease. <i>American Journal of Geriatric Psychiatry</i> , 2010, 18, 136-145.	0.6	199
40	Longitudinal study of normal cognition in Parkinson disease. <i>Neurology</i> , 2015, 85, 1276-1282.	1.5	197
41	Impulse Control and Related Disorders in Parkinson's Disease. <i>International Review of Neurobiology</i> , 2017, 133, 679-717.	0.9	195
42	Screening for impulse control symptoms in patients with de novo Parkinson disease. <i>Neurology</i> , 2013, 80, 176-180.	1.5	194
43	Cognitive impairment in multiple system atrophy: A position statement by the neuropsychology task force of the MDS multiple system atrophy (MODIMSA) study group. <i>Movement Disorders</i> , 2014, 29, 857-867.	2.2	193
44	Impulsive and compulsive behaviors in Parkinson's disease. <i>Movement Disorders</i> , 2009, 24, 1561-1570.	2.2	192
45	CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study. <i>Acta Neuropathologica</i> , 2016, 131, 935-949.	3.9	190
46	Association of <i>GBA</i> Mutations and the E326K Polymorphism With Motor and Cognitive Progression in Parkinson Disease. <i>JAMA Neurology</i> , 2016, 73, 1217.	4.5	185
47	Neurodegeneration Across Stages of Cognitive Decline in Parkinson Disease. <i>Archives of Neurology</i> , 2011, 68, 1562.	4.9	180
48	Diagnosis of Parkinson's disease on the basis of clinical and genetic classification: a population-based modelling study. <i>Lancet Neurology</i> , The, 2015, 14, 1002-1009.	4.9	179
49	Recognition and Treatment of Depression in Parkinson's Disease. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2003, 16, 178-183.	1.2	177
50	Antidepressant studies in Parkinson's disease: A review and meta-analysis. <i>Movement Disorders</i> , 2005, 20, 1161-1169.	2.2	177
51	The Parkinson Anxiety Scale (PAS): Development and validation of a new anxiety scale. <i>Movement Disorders</i> , 2014, 29, 1035-1043.	2.2	173
52	<i>APOE</i> , <i>MAPT</i> , and <i>SNCA</i> Genes and Cognitive Performance in Parkinson Disease. <i>JAMA Neurology</i> , 2014, 71, 1405.	4.5	172
53	Defining and Diagnosing Involuntary Emotional Expression Disorder. <i>CNS Spectrums</i> , 2006, 11, 1-11.	0.7	168
54	New evidence on the management of Lewy body dementia. <i>Lancet Neurology</i> , The, 2020, 19, 157-169.	4.9	167

#	ARTICLE	IF	CITATIONS
55	Neuropsychiatric symptoms and caregiver's burden in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 629-634.	1.1	166
56	Striatal dopamine transporter imaging correlates with anxiety and depression symptoms in Parkinson's disease. <i>Journal of Nuclear Medicine</i> , 2005, 46, 227-32.	2.8	164
57	Mild cognitive impairment is common in Parkinson's disease patients with normal Mini-Mental State Examination (MMSE) scores. <i>Parkinsonism and Related Disorders</i> , 2009, 15, 226-231.	1.1	163
58	Association of Cerebrospinal Fluid Neurofilament Light Protein Levels With Cognition in Patients With Dementia, Motor Neuron Disease, and Movement Disorders. <i>JAMA Neurology</i> , 2019, 76, 318.	4.5	161
59	Initial cognitive decline is associated with cortical thinning in early Parkinson disease. <i>Neurology</i> , 2014, 82, 2017-2025.	1.5	158
60	<i>GBA</i> Variants are associated with a distinct pattern of cognitive deficits in Parkinson's disease. <i>Movement Disorders</i> , 2016, 31, 95-102.	2.2	158
61	Sertraline for the Treatment of Depression in Alzheimer Disease: Week-24 Outcomes. <i>American Journal of Geriatric Psychiatry</i> , 2010, 18, 332-340.	0.6	151
62	[^{99m} Tc]TRODAT-1 SPECT imaging correlates with odor identification in early Parkinson disease. <i>Neurology</i> , 2005, 64, 1716-1720.	1.5	150
63	Alzheimer's disease pattern of brain atrophy predicts cognitive decline in Parkinson's disease. <i>Brain</i> , 2012, 135, 170-180.	3.7	149
64	The neuropsychiatry of Parkinson's disease: advances and challenges. <i>Lancet Neurology</i> , The, 2022, 21, 89-102.	4.9	142
65	Decreased ventral striatal activity with impulse control disorders in Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 1660-1669.	2.2	138
66	Global scales for cognitive screening in Parkinson's disease: Critique and recommendations. <i>Movement Disorders</i> , 2018, 33, 208-218.	2.2	138
67	Association of Antipsychotic Use With Mortality Risk in Patients With Parkinson Disease. <i>JAMA Neurology</i> , 2016, 73, 535.	4.5	136
68	Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative Cohort. <i>Movement Disorders</i> , 2018, 33, 771-782.	2.2	136
69	Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study. <i>Annals of Neurology</i> , 2010, 68, 963-968.	2.8	132
70	Association between cognition and function in patients with Parkinson disease with and without dementia. <i>Movement Disorders</i> , 2010, 25, 1170-1176.	2.2	131
71	Suicide ideation and behaviours after STN and GPi DBS surgery for Parkinson's disease: results from a randomised, controlled trial. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 1113-1118.	0.9	130
72	Circulating brain-enriched microRNAs as novel biomarkers for detection and differentiation of neurodegenerative diseases. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 89.	3.0	129

#	ARTICLE	IF	CITATIONS
73	Genetic influences on cognitive decline in Parkinson's disease. <i>Movement Disorders</i> , 2012, 27, 512-518.	2.2	127
74	Parkinson's disease--Part 1: Pathophysiology, symptoms, burden, diagnosis, and assessment. <i>American Journal of Managed Care</i> , 2008, 14, S40-8.	0.8	127
75	Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease. <i>Annals of Neurology</i> , 2011, 69, 655-663.	2.8	126
76	Task force report: Scales for screening and evaluating tremor: Critique and recommendations. <i>Movement Disorders</i> , 2013, 28, 1793-1800.	2.2	124
77	Genomewide association study of Parkinson's disease clinical biomarkers in 12 longitudinal patients' cohorts. <i>Movement Disorders</i> , 2019, 34, 1839-1850.	2.2	122
78	Dopamine and impulse control disorders in Parkinson's disease. <i>Annals of Neurology</i> , 2008, 64, S93-S100.	2.8	120
79	Course of psychiatric symptoms and global cognition in early Parkinson disease. <i>Neurology</i> , 2014, 83, 1096-1103.	1.5	116
80	Cognitive impairment in nondemented Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, 2483-2495.	2.2	115
81	Cerebrospinal fluid neurogranin concentration in neurodegeneration: relation to clinical phenotypes and neuropathology. <i>Acta Neuropathologica</i> , 2018, 136, 363-376.	3.9	114
82	Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease. <i>PLoS ONE</i> , 2017, 12, e0175674.	1.1	110
83	Psychosis in Parkinson's disease without dementia: Common and comorbid with other non-motor symptoms. <i>Movement Disorders</i> , 2012, 27, 858-863.	2.2	109
84	Genetic risk of Parkinson disease and progression. <i>Neurology: Genetics</i> , 2019, 5, e348.	0.9	109
85	Suicidal and death ideation in Parkinson's disease. <i>Movement Disorders</i> , 2008, 23, 1573-1579.	2.2	106
86	Psychiatric Complications in Parkinson Disease. <i>American Journal of Geriatric Psychiatry</i> , 2005, 13, 844-851.	0.6	105
87	Patterns and Trends in Antipsychotic Prescribing for Parkinson Disease Psychosis. <i>Archives of Neurology</i> , 2011, 68, 899.	4.9	105
88	Incident impulse control disorder symptoms and dopamine transporter imaging in Parkinson disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 864-870.	0.9	105
89	Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson's Disease Progression. <i>Movement Disorders</i> , 2020, 35, 1999-2008.	2.2	104
90	Presentation and Management of Psychosis in Parkinson's Disease and Dementia With Lewy Bodies. <i>American Journal of Psychiatry</i> , 2007, 164, 1491-1498.	4.0	102

#	ARTICLE	IF	CITATIONS
91	Clinical-genetic model predicts incident impulse control disorders in Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 1106-1111.	0.9	102
92	MMSE and MoCA in Parkinson's disease and dementia with Lewy bodies: a multicenter 1-year follow-up study. <i>Journal of Neural Transmission</i> , 2016, 123, 431-438.	1.4	102
93	Longitudinal changes in cognition in early Parkinson's disease patients with REM sleep behavior disorder. <i>Parkinsonism and Related Disorders</i> , 2016, 27, 102-106.	1.1	99
94	Olfactory impairment predicts cognitive decline in early Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2016, 25, 45-51.	1.1	97
95	Elevated CSF GAP43 is Alzheimer's disease specific and associated with tau and amyloid pathology. <i>Alzheimer's and Dementia</i> , 2019, 15, 55-64.	0.4	97
96	Probing the Safety of Medications in the Frail Elderly. <i>Journal of Clinical Psychiatry</i> , 2003, 64, 875-882.	1.1	95
97	Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study. <i>Lancet Neurology</i> , The, 2020, 19, 71-80.	4.9	94
98	Impulsive and compulsive behaviors among Danish patients with Parkinson's disease: Prevalence, depression, and personality. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 22-26.	1.1	92
99	Rivastigmine for mild cognitive impairment in Parkinson disease: A placebo-controlled study. <i>Movement Disorders</i> , 2015, 30, 912-918.	2.2	91
100	Combined Rasagiline and Antidepressant Use in Parkinson Disease in the ADAGIO Study. <i>JAMA Neurology</i> , 2015, 72, 88.	4.5	91
101	Non-motor outcomes depend on location of neurostimulation in Parkinson's disease. <i>Brain</i> , 2019, 142, 3592-3604.	3.7	90
102	Parkinson's disease-related fatigue: A case definition and recommendations for clinical research. <i>Movement Disorders</i> , 2016, 31, 625-631.	2.2	89
103	CSF β -Amyloid 1-42 Predicts Progression to Cognitive Impairment in Newly Diagnosed Parkinson Disease. <i>Journal of Molecular Neuroscience</i> , 2016, 58, 88-92.	1.1	89
104	Longitudinal analyses of cerebrospinal fluid α -Synuclein in prodromal and early Parkinson's disease. <i>Movement Disorders</i> , 2019, 34, 1354-1364.	2.2	89
105	Cognitive and Pathological Influences of Tau Pathology in Lewy Body Disorders. <i>Annals of Neurology</i> , 2019, 85, 259-271.	2.8	88
106	Conversion between Mini-Mental State Examination, Montreal Cognitive Assessment, and Dementia Rating Scale-2 scores in Parkinson's disease. <i>Movement Disorders</i> , 2014, 29, 1809-1815.	2.2	86
107	Baseline prevalence and longitudinal evolution of non-motor symptoms in early Parkinson's disease: the PPMI cohort. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 78-88.	0.9	85
108	Drug Insight: impulse control disorders and dopamine therapies in Parkinson's disease. <i>Nature Clinical Practice Neurology</i> , 2007, 3, 664-672.	2.7	84

#	ARTICLE	IF	CITATIONS
109	Evidence for impaired encoding and retrieval memory profiles in Parkinson disease. <i>Cognitive and Behavioral Neurology</i> , 2004, 17, 195-200.	0.5	84
110	Dimensions of Executive Function in Parkinson's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2005, 20, 140-144.	0.7	83
111	Patterns of cortical thickness associated with impulse control disorders in Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 688-695.	2.2	83
112	High patient satisfaction with telehealth in Parkinson disease. <i>Neurology: Clinical Practice</i> , 2016, 6, 241-251.	0.8	83
113	Impulse Control and Related Disorders in Parkinson's Disease. <i>Neurodegenerative Diseases</i> , 2013, 11, 63-71.	0.8	82
114	The Neuropsychiatry of Parkinson Disease: A Perfect Storm. <i>American Journal of Geriatric Psychiatry</i> , 2019, 27, 998-1018.	0.6	82
115	Cognition in individuals at risk for Parkinson's: Parkinson associated risk syndrome (PARS) study findings. <i>Movement Disorders</i> , 2016, 31, 86-94.	2.2	78
116	Risk factors for early psychosis in PD: insights from the Parkinson's Progression Markers Initiative. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 325-331.	0.9	78
117	Diagnosis and management of Parkinson's disease dementia. <i>International Journal of Clinical Practice</i> , 2008, 62, 1581-1587.	0.8	77
118	Cerebrospinal Fluid Alzheimer's Disease Biomarkers Across the Spectrum of Lewy Body Diseases: Results from a Large Multicenter Cohort. <i>Journal of Alzheimer's Disease</i> , 2016, 54, 287-295.	1.2	77
119	Heterogeneity of Treatment Response to Citalopram for Patients With Alzheimer's Disease With Aggression or Agitation: The CitAD Randomized Clinical Trial. <i>American Journal of Psychiatry</i> , 2016, 173, 465-472.	4.0	77
120	People with Parkinson's disease and normal MMSE score have a broad range of cognitive performance. <i>Movement Disorders</i> , 2014, 29, 1258-1264.	2.2	76
121	A European multicentre survey of impulse control behaviours in Parkinson's disease patients treated with short- and long-acting dopamine agonists. <i>European Journal of Neurology</i> , 2016, 23, 1255-1261.	1.7	76
122	Impulse control disorders in Parkinson's disease: prevalence and possible risk factors. <i>Parkinsonism and Related Disorders</i> , 2009, 15, S110-S113.	1.1	75
123	Naltrexone for impulse control disorders in Parkinson disease. <i>Neurology</i> , 2014, 83, 826-833.	1.5	74
124	Quantitative assessment of finger tapping characteristics in mild cognitive impairment, Alzheimer's disease, and Parkinson's disease. <i>Journal of Neurology</i> , 2018, 265, 1365-1375.	1.8	73
125	Cognitive impairment and PD patients' capacity to consent to research. <i>Neurology</i> , 2013, 81, 801-807.	1.5	71
126	Long-Term Cognitive Decline in Dementia with Lewy Bodies in a Large Multicenter, International Cohort. <i>Journal of Alzheimer's Disease</i> , 2017, 57, 787-795.	1.2	69

#	ARTICLE	IF	CITATIONS
127	CSF tau and β -amyloid predict cerebral synucleinopathy in autopsied Lewy body disorders. <i>Neurology</i> , 2018, 90, e1038-e1046.	1.5	68
128	Psychiatric complications in Parkinson disease. <i>American Journal of Geriatric Psychiatry</i> , 2005, 13, 844-51.	0.6	68
129	Olfactory dysfunction is associated with neuropsychiatric manifestations in Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, 2051-2057.	2.2	67
130	Impulse control disorders in parkinson's disease. <i>Current Neurology and Neuroscience Reports</i> , 2006, 6, 302-306.	2.0	66
131	Advances in the treatment of cognitive impairment in Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 1471-1489.	2.2	65
132	Cognitive profile of LRRK2-related Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 728-733.	2.2	64
133	Effects of Citalopram on Neuropsychiatric Symptoms in Alzheimer's Dementia: Evidence From the CitAD Study. <i>American Journal of Psychiatry</i> , 2016, 173, 473-480.	4.0	63
134	Neurofilament Light Chain as a Biomarker for Cognitive Decline in Parkinson Disease. <i>Movement Disorders</i> , 2021, 36, 2945-2950.	2.2	63
135	Effect of age on geriatric depression scale performance in Parkinson's disease. <i>Movement Disorders</i> , 2007, 22, 1331-1335.	2.2	62
136	Patient versus informant reporting of ICD symptoms in Parkinson's disease using the QUIP: Validity and variability. <i>Parkinsonism and Related Disorders</i> , 2011, 17, 153-155.	1.1	61
137	Fatigue in Parkinson's disease: report from a multidisciplinary symposium. <i>Npj Parkinson's Disease</i> , 2016, 2, .	2.5	61
138	Trial of Pimavanserin in Dementia-Related Psychosis. <i>New England Journal of Medicine</i> , 2021, 385, 309-319.	13.9	61
139	The Movement Disorder Society Nonmotor Rating Scale: Initial Validation Study. <i>Movement Disorders</i> , 2020, 35, 116-133.	2.2	59
140	Parkinson's Disease Subtypes: Critical Appraisal and Recommendations. <i>Journal of Parkinson's Disease</i> , 2021, 11, 395-404.	1.5	56
141	Arguing against the proposed definition changes of PD. <i>Movement Disorders</i> , 2016, 31, 1619-1622.	2.2	55
142	Accuracy of screening instruments for detection of neuropsychiatric syndromes in Parkinson's disease. <i>Movement Disorders</i> , 2016, 31, 270-279.	2.2	55
143	Evolution of Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Early Parkinson's Disease. <i>Annals of Neurology</i> , 2020, 88, 574-587.	2.8	55
144	Risperidone and citalopram concentrations have differential effects on neuropsychiatric scores in elders with dementia and agitation. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 784-792.	1.1	54

#	ARTICLE	IF	CITATIONS
145	Differences in the Presentation and Progression of Parkinson's Disease by Sex. <i>Movement Disorders</i> , 2021, 36, 106-117.	2.2	54
146	International Multicenter Analysis of Brain Structure Across Clinical Stages of Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 2583-2594.	2.2	54
147	<i>TMEM106B</i> Effect on cognition in Parkinson disease and frontotemporal dementia. <i>Annals of Neurology</i> , 2019, 85, 801-811.	2.8	52
148	Impulse control disorder related behaviours during long-term rotigotine treatment: a post hoc analysis. <i>European Journal of Neurology</i> , 2016, 23, 1556-1565.	1.7	51
149	Novel conformation-selective alpha-synuclein antibodies raised against different in vitro fibril forms show distinct patterns of Lewy pathology in Parkinson's disease. <i>Neuropathology and Applied Neurobiology</i> , 2017, 43, 604-620.	1.8	51
150	Do treatment effects vary among differing baseline depression criteria in depression in Alzheimer's disease study Å 2 (DIADS-2)? <i>International Journal of Geriatric Psychiatry</i> , 2011, 26, 573-583.	1.3	49
151	Scales to assess impulsive and compulsive behaviors in Parkinson's disease: Critique and recommendations. <i>Movement Disorders</i> , 2019, 34, 791-798.	2.2	49
152	The Non-Motor Symptoms Scale in Parkinson's disease: Validation and use. <i>Acta Neurologica Scandinavica</i> , 2021, 143, 3-12.	1.0	49
153	Changes in QTc Interval in the Citalopram for Agitation in Alzheimer's Disease (CitAD) Randomized Trial. <i>PLoS ONE</i> , 2014, 9, e98426.	1.1	48
154	Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross-Sectional Study. <i>Movement Disorders</i> , 2020, 35, 833-844.	2.2	48
155	Rasagiline for mild cognitive impairment in Parkinson's disease: A placebo-controlled trial. <i>Movement Disorders</i> , 2016, 31, 709-714.	2.2	47
156	Optimizing olfactory testing for the diagnosis of Parkinson's disease: item analysis of the university of Pennsylvania smell identification test. <i>Npj Parkinson's Disease</i> , 2018, 4, 2.	2.5	47
157	Antidepressant Treatment of Veterans With Parkinson's Disease and Depression: Analysis of a National Sample. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2007, 20, 161-165.	1.2	46
158	Validation of the questionnaire for impulsive-compulsive disorders in Parkinson's disease (QUIP) and the QUIP-rating scale in a German speaking sample. <i>Journal of Neurology</i> , 2014, 261, 936-942.	1.8	46
159	Citalopram for agitation in Alzheimer's disease: Design and methods. <i>Alzheimer's and Dementia</i> , 2012, 8, 121-130.	0.4	45
160	A Consensus Set of Outcomes for Parkinson's Disease from the International Consortium for Health Outcomes Measurement. <i>Journal of Parkinson's Disease</i> , 2017, 7, 533-543.	1.5	45
161	Attitudes Regarding the Etiology and Treatment of Depression in Parkinson's Disease: A Qualitative Study. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2008, 21, 123-132.	1.2	44
162	Patterns of Dementia Treatment and Frank Prescribing Errors in Older Adults With Parkinson Disease. <i>JAMA Neurology</i> , 2019, 76, 41.	4.5	44

#	ARTICLE	IF	CITATIONS
163	Neuropsychiatric symptoms and cognitive abilities over the initial quinquennium of Parkinson disease. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 449-461.	1.7	44
164	The course of depressive symptoms in early Parkinson's disease. <i>Movement Disorders</i> , 2009, 24, 1306-1311.	2.2	43
165	Longitudinal decline in speech production in Parkinson's disease spectrum disorders. <i>Brain and Language</i> , 2017, 171, 42-51.	0.8	43
166	Modifiable vascular risk factors, white matter disease and cognition in early Parkinson's disease. <i>European Journal of Neurology</i> , 2019, 26, 246.	1.7	43
167	The Penn Parkinson's Daily Activities Questionnaire-15: Psychometric properties of a brief assessment of cognitive instrumental activities of daily living in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2016, 25, 21-26.	1.1	42
168	Detecting Mild Cognitive Deficits in Parkinson's Disease: A Comparison of Neuropsychological Tests. <i>Movement Disorders</i> , 2018, 33, 1750-1759.	2.2	42
169	Characterization of Parkinson's disease using blood-based biomarkers: A multicohort proteomic analysis. <i>PLoS Medicine</i> , 2019, 16, e1002931.	3.9	42
170	Cognitive Outcomes After Sertaline Treatment in Patients With Depression of Alzheimer Disease. <i>American Journal of Geriatric Psychiatry</i> , 2012, 20, 1036-1044.	0.6	41
171	Psychiatric issues in cognitive impairment. <i>Movement Disorders</i> , 2014, 29, 651-662.	2.2	41
172	Plasma EGF and cognitive decline in Parkinson's disease and Alzheimer's disease. <i>Annals of Clinical and Translational Neurology</i> , 2016, 3, 346-355.	1.7	41
173	Sedation mediates part of Citalopram's effect on agitation in Alzheimer's disease. <i>Journal of Psychiatric Research</i> , 2016, 74, 17-21.	1.5	41
174	Initial cognitive changes in Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 511-519.	2.2	41
175	Common variant rs356182 near SNCA defines a Parkinson's disease endophenotype. <i>Annals of Clinical and Translational Neurology</i> , 2017, 4, 15-25.	1.7	40
176	Cortical thinning in patients with REM sleep behavior disorder is associated with clinical progression. <i>Npj Parkinson's Disease</i> , 2019, 5, 7.	2.5	40
177	VALIDITY OF THE MoCA AND MMSE IN THE DETECTION OF MCI AND DEMENTIA IN PARKINSON DISEASE. <i>Neurology</i> , 2010, 75, 478-479.	1.5	39
178	Impulse control and related disorders in Mexican Parkinson's disease patients. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 907-910.	1.1	39
179	Cognition and the course of prodromal Parkinson's disease. <i>Movement Disorders</i> , 2017, 32, 1640-1645.	2.2	39
180	Psychiatric Assessment of a Nursing Home Population Using Audiovisual Telecommunication. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2001, 14, 63-65.	1.2	37

#	ARTICLE	IF	CITATIONS
181	Frequency and correlates of co-morbid psychosis and depression in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2006, 12, 427-431.	1.1	37
182	Rivastigmine in Alzheimer's Disease and Parkinson's Disease Dementia. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2011, 26, 443-449.	0.9	37
183	Associations between Cerebrospinal Fluid Biomarkers and Cognition in Early Untreated Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2015, 5, 783-792.	1.5	37
184	Lower plasma apolipoprotein A1 levels are found in Parkinson's disease and associate with apolipoprotein A1 genotype. <i>Movement Disorders</i> , 2015, 30, 805-812.	2.2	37
185	The bidirectional longitudinal relationship between insomnia, depression and anxiety in patients with early-stage, medication-naïve Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2017, 39, 31-36.	1.1	37
186	Large-scale exploratory genetic analysis of cognitive impairment in Parkinson's disease. <i>Neurobiology of Aging</i> , 2017, 56, 211.e1-211.e7.	1.5	37
187	Dopamine transporter imaging predicts clinically defined α -synucleinopathy in REM sleep behavior disorder. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 201-212.	1.7	37
188	Pimavanserin for Parkinson's Disease psychosis: Effects stratified by baseline cognition and use of cognitive-enhancing medications. <i>Movement Disorders</i> , 2018, 33, 1769-1776.	2.2	36
189	Escitalopram for Major Depression in Parkinson's Disease: An Open-Label, Flexible-Dosage Study. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2006, 18, 377-383.	0.9	35
190	ϵ APOE, thought disorder, and SPARE-AD predict cognitive decline in established Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 289-297.	2.2	35
191	Prevalence of Non-Motor Symptoms and Non-Motor Fluctuations in Parkinson's Disease Using the ϵ MDS-NMS. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 231-239.	0.8	35
192	Electroconvulsive therapy for depression in a Parkinson's disease patient with bilateral subthalamic nucleus deep brain stimulators. <i>Parkinsonism and Related Disorders</i> , 2005, 11, 403-406.	1.1	34
193	Is depression in Parkinson's Disease (PD) a specific entity?. <i>Journal of Affective Disorders</i> , 2012, 139, 103-112.	2.0	34
194	Cerebrospinal fluid α -synuclein contributes to the differential diagnosis of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018, 14, 1052-1062.	0.4	34
195	Regional brain amyloid- β accumulation associates with domain-specific cognitive performance in Parkinson disease without dementia. <i>PLoS ONE</i> , 2017, 12, e0177924.	1.1	33
196	Cognition among individuals along a spectrum of increased risk for Parkinson's disease. <i>PLoS ONE</i> , 2018, 13, e0201964.	1.1	33
197	Anxiety Has Specific Syndromal Profiles in Parkinson Disease: A Data-Driven Approach. <i>American Journal of Geriatric Psychiatry</i> , 2014, 22, 1410-1417.	0.6	32
198	Report from a multidisciplinary meeting on anxiety as a non-motor manifestation of Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2019, 5, 30.	2.5	32

#	ARTICLE	IF	CITATIONS
199	Risk of Parkinson's disease dementia related to level I MDS PDâ€MCI. <i>Movement Disorders</i> , 2019, 34, 430-435.	2.2	32
200	Medication Management and Neuropsychological Performance in Parkinson's Disease. <i>Clinical Neuropsychologist</i> , 2012, 26, 45-58.	1.5	31
201	Olfactory dysfunction in Parkinson's disease: Positive effect of cigarette smoking. <i>Movement Disorders</i> , 2015, 30, 859-862.	2.2	31
202	Sex Differences in the Neuropsychiatric Symptoms of Patients With Alzheimerâ€™s Disease. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2018, 33, 450-457.	0.9	31
203	Pilot Study of the International Parkinson and Movement Disorder Societyâ€™sponsored Nonâ€motor Rating Scale (MDSâ€NMS). <i>Movement Disorders Clinical Practice</i> , 2019, 6, 227-234.	0.8	31
204	Impulse Control Disorders in Parkinsonâ€™s Disease. <i>American Journal of Psychiatry</i> , 2019, 176, 5-11.	4.0	31
205	Subjective Cognitive Complaint in Parkinson's Disease Patients With Normal Cognition: Canary in the Coal Mine?. <i>Movement Disorders</i> , 2020, 35, 1618-1625.	2.2	31
206	Benefit finding and relationship quality in Parkinsonâ€™s disease: A pilot dyadic analysis of husbands and wives.. <i>Journal of Family Psychology</i> , 2014, 28, 728-734.	1.0	30
207	Predictors of anxiety in early-stage Parkinson's disease â€“ Results from the first two years of a prospective cohort study. <i>Parkinsonism and Related Disorders</i> , 2017, 43, 49-55.	1.1	30
208	Caregiver report of apathy predicts dementia in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 992-995.	1.1	29
209	Constipation is Associated with Development of Cognitive Impairment in de novo Parkinsonâ€™s Disease: A Longitudinal Analysis of Two International Cohorts. <i>Journal of Parkinson's Disease</i> , 2021, 11, 1209-1219.	1.5	29
210	Should impulse control disorders and dopamine dysregulation syndrome be indications for deep brain stimulation and intestinal levodopa?. <i>Movement Disorders</i> , 2013, 28, 1915-1919.	2.2	28
211	Amyloidâ€Beta Positron Emission Tomography Imaging of Alzheimer's Pathology in Parkinson's Disease Dementia. <i>Movement Disorders Clinical Practice</i> , 2016, 3, 367-375.	0.8	28
212	Antipsychotic Use and Physical Morbidity in Parkinson Disease. <i>American Journal of Geriatric Psychiatry</i> , 2017, 25, 697-705.	0.6	28
213	Cognitive Profile and Markers of Alzheimer Diseaseâ€™Type Pathology in Patients With Lewy Body Dementias. <i>Neurology</i> , 2021, 96, e1855-e1864.	1.5	28
214	Electroconvulsive Therapy for Epilepsy and Major Depression. <i>American Journal of Geriatric Psychiatry</i> , 1998, 6, 180-183.	0.6	27
215	Differences in depression symptoms in patients with Alzheimer's and Parkinson's diseases: evidence from the 15-item Geriatric Depression Scale (GDS-15). <i>International Journal of Geriatric Psychiatry</i> , 2007, 22, 1025-1030.	1.3	27
216	Depression in veterans with Parkinson's disease: frequency, co-morbidity, and healthcare utilization. <i>International Journal of Geriatric Psychiatry</i> , 2007, 22, 543-548.	1.3	26

#	ARTICLE	IF	CITATIONS
217	Impulse control disorders in Parkinson's disease: A 20-year odyssey. <i>Movement Disorders</i> , 2019, 34, 447-452.	2.2	26
218	Pimavanserin versus quetiapine for the treatment of psychosis in Parkinson's disease and dementia with Lewy bodies. <i>Parkinsonism and Related Disorders</i> , 2019, 69, 119-124.	1.1	26
219	Innovating Parkinson's Care: A Randomized Controlled Trial of Telemedicine Depression Treatment. <i>Movement Disorders</i> , 2021, 36, 2549-2558.	2.2	26
220	Impulse Control Disorders and Related Complications of Parkinson's Disease Therapy. <i>Seminars in Neurology</i> , 2017, 37, 186-192.	0.5	25
221	An Alzheimer's Disease-Derived Biomarker Signature Identifies Parkinson's Disease Patients with Dementia. <i>PLoS ONE</i> , 2016, 11, e0147319.	1.1	25
222	Neuropsychologic assessment in collaborative Parkinson's disease research: A proposal from the National Institute of Neurological Disorders and Stroke Morris K. Udall Centers of Excellence for Parkinson's Disease Research at the University of Pennsylvania and the University of Washington. <i>Alzheimer's and Dementia</i> , 2013, 9, 609-614.	0.4	24
223	Use of Latent Variable Modeling to Delineate Psychiatric and Cognitive Profiles in Parkinson Disease. <i>American Journal of Geriatric Psychiatry</i> , 2009, 17, 986-995.	0.6	23
224	Amphetamine positive toxicology screen secondary to bupropion. <i>Depression and Anxiety</i> , 2000, 12, 53-54.	2.0	22
225	Change in agitation in Alzheimer's disease in the placebo arm of a nine-week controlled trial. <i>International Psychogeriatrics</i> , 2015, 27, 2059-2067.	0.6	22
226	Time to Response to Citalopram Treatment for Agitation in Alzheimer Disease. <i>American Journal of Geriatric Psychiatry</i> , 2015, 23, 1127-1133.	0.6	22
227	Phenylthiocarbamide (PTC) Perception in Parkinson Disease. <i>Cognitive and Behavioral Neurology</i> , 2007, 20, 145-148.	0.5	21
228	Neuropsychological Subgroups in Non-Demented Parkinson's Disease: A Latent Class Analysis. <i>Journal of Parkinson's Disease</i> , 2017, 7, 385-395.	1.5	21
229	Hippocampal subfield pathologic burden in Lewy body diseases <i>vs</i>. <i>Alzheimer's disease. Neuropathology and Applied Neurobiology</i> , 2020, 46, 707-721.	1.8	21
230	Pattern of Depressive Symptoms in Parkinson's Disease. <i>Psychosomatics</i> , 2009, 50, 448-454.	2.5	20
231	Frequency and Correlates of Involuntary Emotional Expression Disorder in Parkinson's Disease. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2009, 21, 406-412.	0.9	20
232	Scales to Assess Clinical Features of Progressive Supranuclear Palsy: MDS Task Force Report. <i>Movement Disorders Clinical Practice</i> , 2015, 2, 127-134.	0.8	20
233	Development and initial testing of the Penn Parkinson's Daily Activities Questionnaire. <i>Movement Disorders</i> , 2016, 31, 126-134.	2.2	20
234	The Case for Antipsychotics in Dementia with Lewy Bodies. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 32-35.	0.8	20

#	ARTICLE	IF	CITATIONS
235	Smaller subcortical volume in Parkinson patients with rapid eye movement sleep behavior disorder. <i>Brain Imaging and Behavior</i> , 2019, 13, 1352-1360.	1.1	20
236	Tau pathology associates with in vivo cortical thinning in Lewy body disorders. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 2342-2355.	1.7	20
237	Management of psychiatric disorders in Parkinson's disease. <i>Neurotherapeutics</i> , 2020, 17, 1511-1524.	2.1	19
238	Prodromal Dementia With Lewy Bodies: Evolution of Symptoms and Predictors of Dementia Onset. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2022, 35, 527-534.	1.2	19
239	Case for and against specificity of depression in Alzheimer's disease. <i>Psychiatry and Clinical Neurosciences</i> , 2010, 64, 358-366.	1.0	18
240	Nortriptyline toxicity secondary to interaction with bupropion sustained-release. <i>Depression and Anxiety</i> , 2001, 13, 50-52.	2.0	17
241	Daily Affect in Parkinson Disease Is Responsive to Life Events and Motor Symptoms. <i>American Journal of Geriatric Psychiatry</i> , 2006, 14, 161-168.	0.6	17
242	Designing a new scale to measure anxiety symptoms in Parkinson's disease: item selection based on canonical correlation analysis. <i>European Journal of Neurology</i> , 2013, 20, 1198-1203.	1.7	17
243	Validation of a performance-based assessment of cognitive functional ability in Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 1760-1768.	2.2	17
244	Involuntary emotional expression disorder (IEED) in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2009, 15, 511-515.	1.1	16
245	Cognition in movement disorders: Where can we hope to be in ten years?. <i>Movement Disorders</i> , 2014, 29, 704-711.	2.2	15
246	Therapeutic Development Paths for Cognitive Impairment in Parkinson's Disease: Report of a Regulatory Roundtable. <i>Journal of Parkinson's Disease</i> , 2014, 4, 585-589.	1.5	15
247	Cognitive Functional Abilities in Parkinson's Disease: Agreement Between Patients and Informants. <i>Movement Disorders Clinical Practice</i> , 2019, 6, 440-445.	0.8	15
248	Feasibility and safety of lumbar puncture in the Parkinson's disease research participants: Parkinson's Progression Marker Initiative (PPMI). <i>Parkinsonism and Related Disorders</i> , 2019, 62, 201-209.	1.1	15
249	Pharmacological treatment of apathy in Lewy body disorders: A systematic review. <i>Parkinsonism and Related Disorders</i> , 2019, 60, 14-24.	1.1	15
250	Impulse control and related behaviors in Parkinson's disease with dementia. <i>European Journal of Neurology</i> , 2020, 27, 944-950.	1.7	15
251	Antimuscarinic Anticholinergic Medications in Parkinson Disease: To Prescribe or Deprescribe?. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 1181-1188.	0.8	15
252	Genetic prediction of impulse control disorders in Parkinson's disease. <i>Annals of Clinical and Translational Neurology</i> , 2022, 9, 936-949.	1.7	15

#	ARTICLE	IF	CITATIONS
253	Sertraline for the Treatment of Depression in Alzheimer Disease: Genetic Influences. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2011, 24, 222-228.	1.2	14
254	Hospital care for mental health and substance abuse conditions in Parkinson's disease. <i>Movement Disorders</i> , 2016, 31, 1810-1819.	2.2	14
255	A population pharmacokinetic model for R- and S-citalopram and desmethylcitalopram in Alzheimer's disease patients with agitation. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2016, 43, 99-109.	0.8	14
256	Multimodal in vivo and postmortem assessments of tau in Lewy body disorders. <i>Neurobiology of Aging</i> , 2020, 96, 137-147.	1.5	14
257	Delirious mania in the elderly. <i>International Journal of Geriatric Psychiatry</i> , 2001, 16, 374-377.	1.3	13
258	The depressed brain in Parkinson's disease: Implications for an inflammatory biomarker. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 3004-3005.	3.3	13
259	Statins and Cognition in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2017, 7, 661-667.	1.5	13
260	Integration and Extension of Specialty Mental Healthcare Services to Community Practice in Parkinson Disease. <i>American Journal of Geriatric Psychiatry</i> , 2019, 27, 712-719.	0.6	13
261	Drug and Disease Effects in Parkinson's Psychosis: Revisiting the Role of Dopamine. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 32-36.	0.8	13
262	Quantitative detection of α -Synuclein and Tau oligomers and other aggregates by digital single particle counting. <i>Npj Parkinson's Disease</i> , 2022, 8, .	2.5	13
263	Residents in Personal Psychotherapy. <i>Academic Psychiatry</i> , 1999, 23, 14-19.	0.4	12
264	Pharmacologic Interventions for Psychosis and Agitation in Neurodegenerative Diseases: Evidence About Efficacy and Safety. <i>Psychiatric Clinics of North America</i> , 2005, 28, 941-983.	0.7	12
265	Treatment of Early Parkinson's Disease. <i>European Neurology</i> , 2009, 61, 206-215.	0.6	12
266	Memantine and Cognition in Parkinson's Disease Dementia/Dementia With Lewy Bodies: A Meta-Analysis. <i>Movement Disorders Clinical Practice</i> , 2016, 3, 161-167.	0.8	12
267	Research consent capacity varies with executive function and memory in Parkinson's disease. <i>Movement Disorders</i> , 2016, 31, 414-417.	2.2	12
268	Selection of Normative Group Affects Rates of Mild Cognitive Impairment in Parkinson's Disease. <i>Movement Disorders</i> , 2018, 33, 839-843.	2.2	12
269	From action to abstraction: The sensorimotor grounding of metaphor in Parkinson's disease. <i>Cortex</i> , 2019, 121, 362-384.	1.1	12
270	Predictors of short-term impulsive and compulsive behaviour after subthalamic stimulation in Parkinson disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 1313-1318.	0.9	12

#	ARTICLE	IF	CITATIONS
271	Treatment of Early Parkinson's Disease. <i>European Neurology</i> , 2009, 61, 193-205.	0.6	11
272	Low continuation of antipsychotic therapy in Parkinson disease – intolerance, ineffectiveness, or inertia?. <i>BMC Neurology</i> , 2021, 21, 240.	0.8	11
273	Prevalence of Impulsive-Compulsive Symptoms in Elderly Parkinson's Disease Patients. <i>Journal of Clinical Psychiatry</i> , 2018, 79, .	1.1	11
274	Level I ^{PD} Using Global Cognitive Tests and the Risk for Parkinson's Disease Dementia. <i>Movement Disorders Clinical Practice</i> , 2022, 9, 479-483.	0.8	11
275	Identifying Parkinson's disease subtypes with motor and non-motor symptoms via model-based multi-partition clustering. <i>Scientific Reports</i> , 2021, 11, 23645.	1.6	11
276	Nortriptyline in Geriatric Depression Resistant to Serotonin Reuptake Inhibitors: Case Series. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2001, 14, 28-32.	1.2	10
277	Pharmacologic Management of Psychosis in the Elderly: A Critical Review. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2003, 16, 213-218.	1.2	10
278	Effect of Increasing the Dose and Duration of Sertraline Trial in the Treatment of Depressed Nursing Home Residents. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2003, 16, 109-111.	1.2	10
279	Is Rapid Eye Movement Sleep Behavior Disorder a Risk Factor for Impulse Control Disorder in Parkinson Disease?. <i>Annals of Neurology</i> , 2020, 88, 759-770.	2.8	10
280	Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 1972-1978.	2.2	10
281	Thalamic Dorsomedial Nucleus Free Water Correlates with Cognitive Decline in Parkinson's Disease. <i>Movement Disorders</i> , 2022, 37, 490-501.	2.2	10
282	Second-Generation Issues in the Management of Depression in Nursing Homes. <i>Journal of the American Geriatrics Society</i> , 2002, 50, 2100-2101.	1.3	9
283	French validation of the questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease – Rating Scale (QUIP-RS). <i>Parkinsonism and Related Disorders</i> , 2019, 63, 117-123.	1.1	9
284	Factor Analysis and Clustering of the Movement Disorder Society – Non-Motor Rating Scale. <i>Movement Disorders</i> , 2020, 35, 969-975.	2.2	9
285	Frequency of and risk factors for potentially inappropriate medication use in Parkinson's disease. <i>Age and Ageing</i> , 2020, 49, 786-792.	0.7	9
286	Appropriateness of Applying Cerebrospinal Fluid Biomarker Cutoffs from Alzheimer's Disease to Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2022, 12, 1155-1167.	1.5	9
287	Naltrexone for impulse control disorders in Parkinson disease: A placebo-controlled study. <i>Neurology</i> , 2015, 84, 1386-1387.	1.5	8
288	Citalopram for the Treatment of Agitation in Alzheimer Dementia. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2016, 29, 59-64.	1.2	8

#	ARTICLE	IF	CITATIONS
289	Direct Medical Costs of Dementia With Lewy Bodies by Disease Complexity. <i>Journal of the American Medical Directors Association</i> , 2020, 21, 1696-1704.e5.	1.2	8
290	Introduction: The importance of cognition in movement disorders. <i>Movement Disorders</i> , 2014, 29, 581-583.	2.2	7
291	Is the Parkinson anxiety scale comparable across raters?. <i>Movement Disorders</i> , 2015, 30, 545-551.	2.2	7
292	Development and Validation of the Parkinson's Disease Medication Beliefs Scale (PD-Rx). <i>Journal of Parkinson's Disease</i> , 2016, 6, 383-392.	1.5	7
293	Narrative Organization Deficit in Lewy Body Disorders Is Related to Alzheimer Pathology. <i>Frontiers in Neuroscience</i> , 2017, 11, 53.	1.4	7
294	ADNC-RS, a clinical-genetic risk score, predicts Alzheimer's pathology in autopsy-confirmed Parkinson's disease and Dementia with Lewy bodies. <i>Acta Neuropathologica</i> , 2020, 140, 449-461.	3.9	7
295	Hallucinations and Development of Dementia in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2020, 10, 1643-1648.	1.5	7
296	Plasma <sc>MIA</sc>, <sc>CRP</sc>, and Albumin Predict Cognitive Decline in Parkinson's Disease. <i>Annals of Neurology</i> , 2022, 92, 255-269.	2.8	7
297	Change in the Rate of Restraint Use and Falls on a Psychogeriatric Inpatient Unit: Impact of the Health Care Financing Administration's New Restraint and Seclusion Standards for Hospitals. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2002, 15, 91-94.	1.2	6
298	Intervening in the neuropsychiatric features of Parkinson's disease. <i>Expert Review of Neurotherapeutics</i> , 2007, 7, 699-710.	1.4	6
299	Clinical Vignettes in Parkinson's Disease: A Collection of Unusual Medication-Induced Hallucinations, Delusions, and Compulsive Behaviours. <i>International Journal of Neuroscience</i> , 2011, 121, 472-476.	0.8	6
300	Glad about SAD (PD). <i>Neurology</i> , 2012, 78, 1198-1199.	1.5	6
301	Is Sertraline Treatment or Depression Remission in Depressed Alzheimer Patients Associated with Improved Caregiver Well Being? Depression in Alzheimer's Disease Study 2. <i>American Journal of Geriatric Psychiatry</i> , 2014, 22, 14-24.	0.6	6
302	Parkinson's Disease Impulsive-Compulsive Disorders Questionnaire – Current Short (QUIP-CS) – Translation and validation of content of Portuguese Version. <i>Jornal Brasileiro De Psiquiatria</i> , 2017, 66, 111-115.	0.2	6
303	Lack of independent mood-enhancing effect for dopaminergic medications in early Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2019, 402, 81-85.	0.3	6
304	Nonmotor symptom burden grading as predictor of cognitive impairment in Parkinson's disease. <i>Brain and Behavior</i> , 2021, 11, e02086.	1.0	6
305	Pattern of Depressive Symptoms in Parkinson's Disease. <i>Psychosomatics</i> , 2009, 50, 448-454.	2.5	6
306	Neuropsychiatric Symptoms in Parkinson Disease and Dementia with Lewy Bodies: What Geriatric Psychiatry Can Learn. <i>American Journal of Geriatric Psychiatry</i> , 2013, 21, 497-500.	0.6	5

#	ARTICLE	IF	CITATIONS
307	Measurement properties from the Brazilian Portuguese version of the QUIP-RS. Npj Parkinson's Disease, 2020, 6, 6.	2.5	5
308	Whole Clinic Research Enrollment in Parkinson's Disease: The Molecular Integration in Neurological Diagnosis (MIND) Study. Journal of Parkinson's Disease, 2021, 11, 757-765.	1.5	5
309	Psychometric Properties of the Clinical Dementia Rating Scale Sum of Boxes in Parkinson's Disease. Journal of Parkinson's Disease, 2021, 11, 737-745.	1.5	5
310	Neurofilament Light Chain Related to Longitudinal Decline in Frontotemporal Lobar Degeneration. Neurology: Clinical Practice, 2021, 11, 105-116.	0.8	5
311	Non-tremor motor dysfunction in Lewy body dementias is associated with AD biomarkers. Parkinsonism and Related Disorders, 2022, 100, 33-36.	1.1	5
312	Characterization of Non-Motor Fluctuations Using the Movement Disorder Society <sc>Non-Motor</sc> Rating Scale. Movement Disorders Clinical Practice, 2022, 9, 932-940.	0.8	5
313	Disorders of mood and affect in Parkinson's disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2007, 83, 421-433.	1.0	4
314	Principal components analysis of agitation outcomes in Alzheimer's disease. Journal of Psychiatric Research, 2016, 79, 4-7.	1.5	4
315	Progress Regarding Parkinson's Disease Psychosis: It's No Illusion. Movement Disorders Clinical Practice, 2016, 3, 431-434.	0.8	4
316	Psychiatric Issues in Parkinson's Disease. Blue Books of Neurology, 2010, 34, 213-228.	0.1	3
317	Both the body and brain benefit from exercise: Potential win-win for Parkinson's disease patients. Movement Disorders, 2011, 26, 607-607.	2.2	3
318	Impulse control disorders and related behaviors. , 2013, , 140-152.		3
319	The Danger of Not Treating Parkinson Disease Psychosis"Reply. JAMA Neurology, 2016, 73, 1156.	4.5	3
320	Diagnosing and Treating Depression in Patients With Parkinson's Disease. Psychiatric Annals, 2004, 34, 298-304.	0.1	3
321	Validation of the Japanese Version of the Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease-Rating Scale (QUIP-RS). Parkinson's Disease, 2022, 2022, 1-6.	0.6	3
322	Therapeutic options for emotional lability: Current and emerging treatments. American Journal of Geriatric Pharmacotherapy, 2005, 3, 12-15.	3.0	2
323	Screening for impulse control symptoms in patients with de novo Parkinson disease: A case-control study. Neurology, 2013, 81, 694-695.	1.5	2
324	Treatment changes among older patients with dementia treated with antipsychotics. International Journal of Geriatric Psychiatry, 2015, 30, 1238-1249.	1.3	2

#	ARTICLE	IF	CITATIONS
325	Cognitive decline before diagnosis of Parkinson's disease – Authors' reply. <i>Lancet Neurology</i> , The, 2017, 16, 262.	4.9	2
326	Reply: MoCA for cognitive screening in Parkinson's disease: Beware of floor effect. <i>Movement Disorders</i> , 2018, 33, 499-500.	2.2	2
327	Annual Prevalence of Use of Potentially Inappropriate Medications for Treatment of Affective Disorders in Parkinson's Disease. <i>American Journal of Geriatric Psychiatry</i> , 2021, 29, 35-47.	0.6	2
328	Movement in Aesthetic Experiences: What We Can Learn from Parkinson Disease. <i>Journal of Cognitive Neuroscience</i> , 2021, 33, 1329-1342.	1.1	2
329	A Model to Assess the Outcomes Associated With Dementia With Lewy Bodies. <i>Alzheimer Disease and Associated Disorders</i> , 2021, 35, 68-74.	0.6	2
330	Early cognitive impairment. , 0, , 163-176.		1
331	Neuropsychiatric aspects of the on/off phenomenon. , 2013, , 275-284.		1
332	Decision-Making Deficits Associated with Amyloidosis in Lewy Body Disorders. <i>Frontiers in Human Neuroscience</i> , 2017, 10, 693.	1.0	1
333	At a crossroads: Revisiting mild cognitive impairment in Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 501-502.	2.2	1
334	Assessment of Affective-Behavioral States in Parkinson's Disease Patients: Towards a New Screening Tool. <i>Journal of Parkinson's Disease</i> , 2021, 11, 1417-1430.	1.5	1
335	Clinical and demographic changes over ten years on a psychogeriatric inpatient unit. <i>Annals of Clinical Psychiatry</i> , 2000, 12, 227-31.	0.6	1
336	Drs. Weintraub and Hurtig Reply. <i>American Journal of Psychiatry</i> , 2008, 165, 261-261.	4.0	0
337	A failure to communicate: Preliminary evidence for cortico-striatal dysconnection with pathological gambling in Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, 193-194.	2.2	0
338	The Diagnosis and Longitudinal Course of Common Movement Disorders in Geriatric Psychiatry. <i>American Journal of Geriatric Psychiatry</i> , 2013, 21, S34-S35.	0.6	0
339	The boundaries of Parkinson's disease dementia and dementia with Lewy bodies. , 0, , 40-52.		0
340	Clinical assessment: mood and motivation. , 0, , 65-72.		0
341	Diagnosis and biomarkers: CSF. , 0, , 97-108.		0
342	Apathy. , 0, , 131-139.		0

#	ARTICLE	IF	CITATIONS
343	Parkinsonâ€™s disease dementia. , 0, , 177-191.		0
344	Sleep disturbances. , 0, , 192-210.		0
345	Understanding Psychosis in Parkinson's Disease. American Journal of Geriatric Psychiatry, 2014, 22, S35-S36.	0.6	0
346	Efficacy of rasagiline in patients with Parkinsonâ€™s disease and mild cognitive impairment: results from moderato, a 24-week randomized, double-blind, placebo-controlled trial. Journal of the Neurological Sciences, 2015, 357, e262.	0.3	0
347	Reply to letter to the editor â€“Independent application of MoCA/MMSE conversionâ€™ by Armstrong et al.. Movement Disorders, 2015, 30, 1711-1711.	2.2	0
348	Lessons and challenges of trials for cognitive and behavioral complications of Parkinson's disease. , 0, , 325-336.		0
349	0075 Neural Correlates of Cognitive Fatigue in Parkinson Disease. Sleep, 2020, 43, A30-A30.	0.6	0
350	Clinical Followâ€™up of Parkinson's Disease With Newly Prescribed Quetiapine. Movement Disorders, 2020, 35, 1690-1692.	2.2	0
351	Does a Positive Amyloid Scan Always Mean Alzheimer Disease?. , 2020, , 99-102.		0
352	I Donâ€™t Know When to Stop. , 2020, , 149-152.		0
353	Caring for the Caregiver. , 2020, , 155-157.		0
354	Cognitive Decline Is Only Part of the Story. , 2020, , 4-6.		0
355	Not Recognizing the Impostor. , 2020, , 64-66.		0
356	Cognitive Impairment as an Unexpected Guest. , 2020, , 75-77.		0
357	â€œThat Is Not How I Feelâ€™, , 2020, , 96-98.		0
358	The 36-Hour Day (3rd Edition). American Journal of Geriatric Psychiatry, 2001, 9, 179-179.	0.6	0